Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
177Lu-DOTA-chCE7
- Development stage
- Preclinical
- Lead developer
- Paul Scherrer Institute
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
**177Lu-DOTA-chCE7** is an investigational anti-L1 cell adhesion molecule radioimmunoconjugate for targeted cancer therapy. It comprises the internalizing chimeric monoclonal antibody chCE7, conjugated to DOTA and labeled with the beta-emitting radionuclide lutetium-177. Binding to L1CAM promotes tumor-cell-associated retention and internalization of the radioimmunoconjugate, delivering cytotoxic radiation to L1CAM-expressing tumors. Development has been preclinical, with ovarian cancer xenograft studies demonstrating antitumor activity; it has not been identified as a marketed product or clinical-stage program. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/17045168/))
- Other names
- 177Lu-DOTA-chCE7
02
Targets
L1CAM
Beyond the preview
Go deeper on 177Lu-DOTA-chCE7.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 177Lu-DOTA-chCE7.